Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Boehringer Ingelheim
Argus Health
Cantor Fitzgerald

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202022

« Back to Dashboard
NDA 202022 describes EDURANT, which is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the EDURANT profile page.

The generic ingredient in EDURANT is rilpivirine hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rilpivirine hydrochloride profile page.

Summary for NDA: 202022

Formulation / Manufacturing:see details

Pharmacology for NDA: 202022

Suppliers and Packaging for NDA: 202022

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
rilpivirine hydrochloride
TABLET;ORAL 202022 NDA Janssen Products, LP 59676-278 59676-278-01 30 TABLET, FILM COATED in 1 BOTTLE (59676-278-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG BASE
Approval Date:May 20, 2011TE:RLD:Yes
Patent:6,838,464Patent Expiration:Feb 26, 2021Product Flag?YSubstance Flag?YDelist Request?
Patent:7,067,522Patent Expiration:Dec 20, 2019Product Flag?YSubstance Flag?YDelist Request?
Patent:7,638,522Patent Expiration:Apr 14, 2023Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Cantor Fitzgerald
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus